GlassScriptPhysician profile
Tami J Santo
NPI 1801224688
$13,419.58
in general payments reported to CMS, 2019-2025
32 companies · $2,317 in 2025
The $2,317 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,733 · 2022: $3,333 · 2023: $3,199 · 2024: $2,838 · 2025: $2,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,930 · Education: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,929.50 |
| Education | $424.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,483.03 | 2021-2025 | |
| Ucb, INC. | $1,491.13 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,027.15 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $996.08 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $841.39 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $796.11 | 2021-2025 | |
| Pfizer INC. | $776.49 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $597.31 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $554.19 | 2023-2024 | Vtama |
| Incyte Corporation | $533.71 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $508.31 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $464.30 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Sun Pharmaceutical Industries INC. | $362.12 | 2021-2024 | Ilumya, Absorica Ld, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $232.37 | 2021-2025 | Siliq, Targretin, Arazlo |
| Lnhc, INC | $212.41 | 2025 | Zelsuvmi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $206.25 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $165.36 | 2022 | |
| Botanix Sb INC | $154.36 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $150.86 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $150.37 | 2023-2025 | Zoryve |
| Almirall LLC | $149.28 | 2021-2024 | Klisyri, Seysara |
| Leo Pharma INC. | $129.72 | 2021-2024 | Adbry |
| Janssen Scientific Affairs, LLC | $117.93 | 2022 | |
| Paratek Pharmaceuticals, INC. | $92.57 | 2021-2022 | |
| Epi Health, LLC | $40.92 | 2022 | |
| Sebela Pharmaceuticals INC. | $35.44 | 2021-2022 | |
| Organon LLC | $34.42 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.25 | 2024 | Spevigo |
| Journey Medical Corporation | $24.44 | 2023 | |
| Sensus Healthcare, INC. | $23.80 | 2021 | |
| Vyne Pharmaceuticals INC. | $20.46 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.05 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Santo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.